Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Everyday Practices
45%
Psoriasis
41%
Dupilumab
40%
Area Index
38%
Severity Index
38%
Adverse Events
31%
Atopic Dermatitis
29%
Moderate-to-severe Atopic Dermatitis
25%
Index Score
24%
Eczema
20%
Pruritus
19%
Psoriasis Severity
17%
Psoriasis Area
17%
Patient-reported Outcomes
16%
Numeric Rating Scale
16%
Multicenter Cohort Study
14%
Serious Infection
13%
Activities of Daily Living
13%
PASI90
13%
Registry Study
13%
Older Patients
13%
Infection Infection
13%
5-year Outcomes
13%
Respiratory Infection
13%
Real-world Effectiveness
13%
Practice-based Studies
13%
Low Disease Activity
13%
Drug Survival
13%
Young Patients
13%
Psoriasis Disease
13%
INIS
patients
100%
psoriasis
53%
dermatitis
53%
safety
43%
comparative evaluations
26%
diseases
21%
adults
17%
eczema
15%
drugs
13%
risks
13%
evaluation
13%
levels
13%
proteins
13%
adolescents
13%
refractories
13%
data
13%
age groups
5%
interleukins
5%
Pharmacology, Toxicology and Pharmaceutical Science
Psoriasis
40%
Dupilumab
40%
Atopic Dermatitis
40%
Biological Product
34%
Adverse Event
26%
Pruritus
14%
Plasma Protein
13%
Respiratory Tract Infection
13%
Disease Activity
13%
Tralokinumab
13%
Infection
13%
Eczema
13%
Immunoglobulin E
13%
Secukinumab
7%
Guselkumab
7%
Etanercept
7%
Comorbidity
5%
Ixekizumab
5%
Ustekinumab
5%
Adalimumab
5%